Research
Quarterly Trends Report

Healthcare trends, oncological developments and the saturated American cannabis market

  • Public Equity
  • Healthcare
  • Global

Third Bridge Forum conducted over 180 interviews throughout the first quarter of 2019. Our Interviews covered pharmaceuticals, biotechnology, the lifesciences, and healthcare equipment and services, providing key insights from senior specialists operating in China, North America and Europe.

Originator drug manufacturers in China 

The pilot scheme for tendering with minimum procurement quantities in China, aimed at reducing the price of drugs within the country, has already had a major impact on the valuation of pharmaceutical companies. A former Deputy General Manager at Yangtze River Pharmaceutical Group, Beijing Haiyan Pharmaceutical said that, “after the first batch of winning bids was announced on 7th December” by the government, “the combined valuation of 300 listed pharmaceutical companies decreased by about RMB 30bn in only two days.”

Read More

Submit your details to access the latest Quarterly Trends Report from Third Bridge.

Additional Content